Dongdong Zhan

Dongdong Zhan

Auto-generated profile, based on publicly available information

Dongdong Zhan

State Key Laboratory of Medical Proteomics, National Center for Protein Sciences (Beijing), Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
ZHZitian Huo
Zitian Huo
YDYaqi Duan
Yaqi Duan
DZDongdong Zhan
Dongdong Zhan
XXXizhen Xu
Xizhen Xu
NZNairen Zheng
Nairen Zheng
YWYi Wang
Yi Wang
Small cell lung cancer (SCLC) is a highly malignant and heterogeneous cancer with limited therapeutic options and prognosis prediction models. Here, we analyzed formalin-fixed, paraffin-embedded (FFPE) samples of surgical resections by proteomic profiling, and stratified SCLC into three proteomic subtypes (S-I, S-II, and S-III) with distinct clinical outcomes and chemotherapy responses. The proteomic subtyping was an independent prognostic factor and performed better than current tumor–node–metastasis or Veterans Administration Lung Study Group staging methods. The subtyping results could be further validated using FFPE biopsy samples from an independent cohort, extending the analysis to both surgical and biopsy samples. The signatures of the S-II subtype in particular suggested potential benefits from immunotherapy. Differentially overexpressed proteins in S-III, the worst prognostic subtype, allowed us to nominate potential therapeutic targets, indicating that patient selection may bring new hope for previously failed clinical trials. Finally, analysis of an independent cohort of SCLC patients who had received immunotherapy validated the prediction that the S-II patients had better progression-free survival and overall survival after first-line immunotherapy. Collectively, our study provides the rationale for future clinical investigations to validate the current findings for more accurate prognosis prediction and precise treatments.

17 August 2026 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
HXHui Xie
Hui Xie
CXCaixia Xu
Caixia Xu
BZBinghan Zhou
Binghan Zhou
FCFang Cheng
Fang Cheng
HXHongliang Xu
Hongliang Xu
GWGuangshun Wang
Guangshun Wang